Fig. 7: Disturbing the TRIB3/MYC interaction attenuates lymphoma in mice.
a The strategy for investigating the anti-BCL effects of PCM4 on MycEμ mice in vivo. b, c The data represent the statistical analyses of spleen and LN weights in MycEμ mice (5 months old; n = 7 per group) treated with the indicated agents. Data are represented as means ± SEM. Statistical significance was determined by two-tailed Student’s t test. P value: 0.016; 0.0108, and 0.0038 (b); 0.003, 0.0003, 7.34 × 10−5 (c). d Representative images of Ki67 staining (left) and statistical analyses of Ki67-positive cells (right) in the spleens of MycEμ mice (5 months old; n = 12 per group) treated with the indicated agents. Scale bar, 50 μm. Data are represented as means ± SEM. Statistical significance was determined by two-tailed Student’s t test. P value: 1.28 × 10−9, 7.86 × 10−10, and 1.13 × 10−9. e The tumorigenicity of BCL cells from the indicated mice was compared by limiting dilution transplantation into NSG mice; n = 8 mice per group. f PCM4 disturbed the TRIB3/MYC interaction in vivo. Spleen lysates from the indicated mice (5 months old) were IP with an anti-TRIB3 Ab and blotted with an anti-MYC Ab. The data are representative of three independent assays. g PCM4-reduced MYC expression. LN and spleen extracts from the indicated mice (5 months old) were blotted with an anti-MYC Ab. The data are presented as representative from three independent experiments. h Kaplan–Meier survival curves for MycEμ BCL mice treated with the indicated agents (n = 10 per group). Statistical difference was determined by two-sided log-rank test. P value: 0.0214 (DOX + PCM4 vs. DOX + PCON). Source data are provided as a Source Data file.
